Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 98,700 shares, a growth of 174.9% from the September 15th total of 35,900 shares. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.8% of the shares of the company are sold short.

Windtree Therapeutics Stock Up 4.6 %

Shares of WINT stock traded up $0.03 during mid-day trading on Friday, hitting $0.73. 262,794 shares of the company’s stock were exchanged, compared to its average volume of 562,928. The stock has a market cap of $433,237.00, a price-to-earnings ratio of -0.03 and a beta of 0.55. The stock has a 50-day simple moving average of $6.00 and a two-hundred day simple moving average of $5.15. Windtree Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $27.00.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Monday, August 19th. The company reported ($20.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.11) by ($12.80). As a group, analysts anticipate that Windtree Therapeutics will post -2.38 earnings per share for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.